What are the precautions when taking neratinib/neratinib?

Neratinib/NeratinibIndicated for long-term adjuvant treatment of early-stage HER2overexpression/ amplified breast cancer after trastuzumab-based adjuvant therapy< span>, the combination of neratinib and capecitabine for the treatment of advanced or metastatic HER2-positive breast cancer is suitable for patients with metastatic breast cancer who have received ≥2 secondary anti-HER2 treatments.

What are the precautions for taking neratinib/neratinib?

1.Diarrhea. Severe diarrhea and sequelae, such as dehydration, hypotension, and renal failure, have occurred during treatment withneratinib.

Antidiarrheal prophylaxis has been shown to reduce the incidence and severity of diarrhea. Instruct patients to use loperamide for antidiarrheal prophylaxis while taking the first dose of neratinib and to continue using it for the first 56 days of treatment; after the 56th day of treatment, titrate the dose to achieve 1-2 bowel movements per day and no more than 16 bowel movements per day. mgLoperamide[See Dosage and Administration(2.1)]. Consider adding other drugs to loperamide as clinically indicated. Alternatively, a 2weeks of neratinib dose escalation may be considered for diarrhea management before initiating the recommended neratinibtreatment regimen. For patients taking escalating doses of neratinib, the median time to first onset of grade ≥3 diarrhea was 45 days (range, 15-1 32 days), and the median cumulative duration of grade ≥3 diarrhea was 2.5 days (range 1-6 days). 13%occurred3grade diarrhea. Monitor the patient for diarrhea and treat with additional antidiarrheal medications as needed. When severe diarrhea with dehydration occurs, administer fluids and electrolytes as needed, interrupt neratinib and reduce subsequent doses. Stool cultures are performed as clinically indicated to exclude infectious causes of grade 3 or 4 diarrhea or any grade of diarrhea with complex features (dehydration, fever, neutropenia).

2.Hepatotoxicity. Neratinib has been associated with hepatotoxicity, characterized by increased liver enzymes. Total bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase should be measured monthly for 3 months prior to initiating neratinibtreatment and then every 3months during treatment as clinically indicated. Patients who develop grade 3 diarrhea or any signs or symptoms of hepatotoxicity (eg, worsening fatigue, nausea, vomiting, right upper quadrant tenderness, fever, rash, or eosinophilia) should also undergo these tests.

3.Embryo-Fetal toxicity. Based on the results of animal studies and its mechanism of action, the use of nereid in pregnant women may cause harm to the fetus. In animal reproduction studies, administration of neratinib to pregnant rabbits during organogenesis resulted in miscarriage, embryonic-fetal death, and fetal malformations, with a maternal AUC that was approximately 0.2 times the AUC of patients receiving the recommended dose. Inform pregnant women of potential risks to the fetus. Advise females of childbearing potential to use effective contraception during treatment and for at least1 months after the last dose. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.